Both in Pharmaceuticals
Gossamer Bio vs Spero Therapeutics
Over the past year GOSS returned −95.1% and SPRO returned −56.3%; their daily moves had a correlation of -0.02.
GOSS −95.1% SPRO −56.3%Growth of $1, one year, split-adjusted
| Metric | GOSS | SPRO |
|---|---|---|
| Price | $9.45 | $1.04 |
| Market cap | $57.8M | $60.6M |
| Today | −8.96% | −1.89% |
| 1 month | −11.8% | −12.6% |
| 6 months | −66.3% | −58.4% |
| Year to date | −96.2% | −55.4% |
| 1 year | −95.1% | −55.9% |
| Revenue growth (YoY) | −19.6% | −100.0% |
| Gross margin | 100.0% | — |
| Net margin | 182.9% | — |
| P/E (TTM) | — | 8.2× |
| Price / sales | 1.1× | 1.3× |
| Net cash | $20.9M | $50.7M |
| Dividend yield | — | — |
| Volatility (60d) | 1,265.9% | 58.8% |
| Short % of float | 24.9% | 2.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).